LENSAR Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LNSR research report →
Range $9 – $13
Price Chart
About the company
LENSAR, Inc. , a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
- CEO
- Nicholas T. Curtis
- IPO
- 2020
- Employees
- 150
- HQ
- Orlando, FL, US
Get TickerSpark's AI analysis on LNSR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $54.83M
- P/E
- 3.72
- Fwd P/E
- 21.94
- PEG
- 0.01
- P/S
- 0.91
- P/B
- 5.00
- EV/EBITDA
- 1.26
- Div Yield
- 0.00%
- Gross Margin
- 52.03%
- Op Margin
- -3.29%
- Net Margin
- 56.07%
- ROE
- 549.37%
- ROIC
- -4.12%
Latest fiscal year · YoY change
- Revenue
- $58.44M+9.2%
- Gross Profit
- $27.12M+4.9%
- Op Income
- $-24,578,000
- Net Income
- $-34,280,000-9.2%
- EPS
- $-2.87-5.1%
- OCF Growth
- -551.9%
- FCF Growth
- -513.5%
- 52W High
- $12.94
- 52W Low
- $4.30
- 50D MA
- $6.09
- 200D MA
- $6.91
- Beta
- 1.03
- RSI (14)
- 30
- Avg Volume
- 66.76K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
LENSAR posted a seasonally softer third quarter, but recurring revenue, procedure volume, installed base and profitability metrics all improved year over year.· November 10, 2026
- Total revenue was $14.1 million, down 1% from $14.3 million a year ago, as lower system sales offset recurring revenue growth.
- Recurring revenue rose 17% to $12.6 million and represented 89% of revenue, up from 75% last year.
- Procedure volume increased 12% to 52,545 and procedure revenue grew 17% to $9.2 million, while market share rose to 24.5% from 24.1% in Q2.
- Gross margin improved to 58% from 42% last year, and adjusted EBITDA turned positive at $1.7 million.
- Management said Q4 should see continued ramp in OUS activity, with new robotic docking features targeted for introduction by the end of Q1 2027.
LENSAR reported third-quarter 2026 revenue of $14.1 million, down 1% year over year from $14.3 million. System revenue was $1.5 million versus $3.5 million a year ago, recurring revenue was $12.6 million versus $10.8 million, and procedure revenue was approximately $9.2 million, up 17%. Procedure volume rose 12% to 52,545 from 46,811, gross margin expanded to 58% from 42%, operating loss narrowed to about $1.4 million from $7.6 million, and adjusted EBITDA was positive $1.7 million versus negative $300,000. Cash and investments were $12.6 million at September 30, 2026, with $900,000 of cash burn in the quarter, and the company added a $10 million revolving credit line for total available liquidity of $22.6 million. For the fourth quarter, management expects $1 million to $2 million of additional cash burn and said the company should get closer to breakeven at some point in 2027.
Nick Curtis framed the quarter as seasonally weak but consistent with expectations, emphasizing that the important underlying trends remained positive. He highlighted growth in recurring revenue, procedures, installed base and market share, and said the company is rebuilding commercial momentum after earlier disruption and the Alcon-related transition. His tone was constructive and optimistic, especially around international reactivation and the next phase of ALLY innovation, including robotic docking features by the end of Q1 2027.
Mike Rossi focused on liquidity, margin improvement and expense discipline. He said cash and investments were $12.6 million, cash burn was $900,000, and a new $10 million revolver lifted available liquidity to $22.6 million. On the P&L, he cited 58% gross margin versus 42% a year ago, SG&A of about $8.1 million versus $12 million, R&D of about $1.3 million, and adjusted EBITDA of $1.7 million; he also said the quarter benefited from mix and lower service costs, though those lower service costs likely would not repeat. He guided to $1 million to $2 million of cash burn for the rest of the year and said the company should get closer to breakeven in 2027.
Analysts focused on the system backlog and whether the commercial funnel is tightening, especially after the Alcon transaction ended. Management said the slower pace reflected a combination of distributor disruption outside the U.S., summer seasonality, and reimbursement changes in markets such as Germany and Switzerland, but Curtis said he is seeing activity come back and is “more optimistic” into year-end and 2027. Questions also centered on innovation timing; management said robotic docking should arrive by the end of Q1 into Q2 2027, while larger integration projects such as phaco and microscope-related initiatives are longer-term, with some potential paths taking 18 months to under 2 years and others 3 to 5 years.
The bull case is that the business is shifting toward a more recurring, higher-margin profile: recurring revenue, procedure volume, procedure revenue and market share all increased year over year, while gross margin and adjusted EBITDA improved sharply. Management also pointed to a larger installed base, a 12-unit backlog, renewed OUS activity, and a pipeline of product enhancements that could extend the platform's differentiation.
The main risks are still visible in the results: total revenue declined year over year because system sales were lumpy, OUS activity was disrupted by the Alcon process and seasonality, and management described international operations as still a “work in progress.” Cash remains limited at $12.6 million despite the new revolver, and the company expects $1 million to $2 million of additional cash burn in the rest of the year before getting closer to breakeven only sometime in 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.0%
- Shares Outstanding
- 12.29M
- Float Shares
- 8.85M
of shares held by institutions
80 13F filers
Buy/sell ratio 0.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Brandes Investment Partners, LP | 1.25M | ▲ 178.98K |
| Vanguard Group Inc | 515.73K | ▲ 8.12K |
| Vanguard Capital Management LLC | 402.81K | 0 |
| Rbf Capital, LLC | 227.91K | ▲ 39.25K |
| Marshall Wace, Llp | 184.00K | ▲ 184.00K |
| Blackrock, Inc. | 166.38K | ▼ 18.65K |
| Css LLC/Il | 120.45K | ▼ 43.00K |
| Evernest Financial Advisors, LLC | 118.10K | ▲ 52.10K |
| Geode Capital Management, LLC | 111.70K | ▼ 2.63K |
| Mink Brook Asset Management LLC | 100.00K | ▲ 100.00K |
| Dcf Advisers, LLC | 94.00K | ▼ 24.22K |
| Millennium Management LLC | 88.23K | ▼ 32.45K |
Held by 36 ETFs
Biggest fund positions in LNSR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | O'Farrell Elizabeth G. | other | 22,214 |
| Nov 18, 26 | O'Farrell Elizabeth G. | other | 10,961 |
| Nov 17, 26 | O'Farrell Elizabeth G. | sell | 22,214 |
| Nov 18, 26 | O'Farrell Elizabeth G. | sell | 10,961 |
| Nov 17, 26 | O'Farrell Elizabeth G. | other | 22,214 |
| Nov 18, 26 | O'Farrell Elizabeth G. | other | 10,961 |
| Nov 11, 26 | Winer Gary M | other | 4,169 |
| Jun 3, 26 | HAMMER TODD B | other | 17,421 |
| Jun 3, 26 | ELLIS THOMAS B | other | 17,421 |
| Jun 3, 26 | Wong Kendra | other | 13,066 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LNSR coverage
Recent articles, reports, and earnings notes.
No research on LNSR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LNSR report →LENSAR Q3 Earnings Call Highlights
marketbeat.com · Nov 10
LENSAR, Inc. (LNSR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
LENSAR® Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 10
LENSAR® to Report Third Quarter 2026 Results on November 10th, 2026
globenewswire.com · Nov 3
Cedar Grove Capital Q3 2026 Portfolio Update
seekingalpha.com · Oct 7
LENSAR Q2 Earnings Call Highlights
marketbeat.com · Aug 13
LENSAR, Inc. (LNSR) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 13
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
globenewswire.com · Aug 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.